EGFR-tyrosine kinase inhibitors (EGFR-TKIs) significantly prolong the overall survival (OS) of patients with advanced EGFR-mutated (EGFR +) NSCLC [2, 3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.